Brief: Design Therapeutics Reports Positive Data From Single-Ascending Dose Trial Of DT-216 For The Treatment Of Friedreich Ataxia And Portfolio Progress
07/12/2022 21:27
Dec 7 (Reuters) - Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS REPORTS POSITIVE DATA FROM
SINGLE-ASCENDING
DOSE TRIAL OF DT-216 FOR THE TREATMENT OF FRIEDREICH ATAXIA AND
PORTFOLIO PROGRESS
* DESIGN THERAPEUTICS INC - ADVANCING MYOTONIC DYSTROPHY
TYPE-1
GENETAC(TM) LEAD MOLECULES; IND EXPECTED IN 2024
* DESIGN THERAPEUTICS INC - DT-216 WAS GENERALLY
WELL-TOLERATED
AND RESULTED IN A MORE THAN DOUBLING OF FRATAXIN MRNA IN
PATIENTS WITH FRIEDREICH ATAXIA
* DESIGN THERAPEUTICS-DT-168, FOR TREATMENT OF FUCHS
ENDOTHELIAL
CORNEAL DYSTROPHY ADMINISTERED AS AN EYE DROP DROP IN TRIAL;
EXPECTS IND IN 2023
Source text for Eikon: ID:nGNXgzxVt
Further company coverage: DSGN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1